Imbruvica

Imbruvica (ibrutinib) is a targeted cancer therapy used primarily to treat certain blood cancers, such as chronic lymphocytic leukemia and mantle cell lymphoma. It works by blocking a specific protein called Bruton's tyrosine kinase (BTK), which cancer cells rely on to grow and survive. By inhibiting BTK, Imbruvica helps slow or stop the progression of the disease, encouraging cancer cell death. It is taken orally as a pill and is often used when other treatments have not been effective. Imbruvica's targeted approach allows it to be effective with potentially fewer side effects than traditional chemotherapy.